Cargando…

Atypical HUS and Crohn’s disease—interference of intestinal disease activity with complement-blocking treatment

BACKGROUND: In atypical hemolytic-uremic syndrome (aHUS), various defects of the complement system have been reported to explain pathophysiology. Therapeutic options for complement inhibition are well-recognized; however, the links between various immune-derived diseases and aHUS are unclear, and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Horváth, Orsolya, Kelen, Kata, Prohászka, Zoltán, Hosszú, Ádám, Szabó, Attila J, Reusz, George S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445858/ https://www.ncbi.nlm.nih.gov/pubmed/34328541 http://dx.doi.org/10.1007/s00467-021-05167-9

Ejemplares similares

Immunosuppressive Therapy of Antibody-Mediated aHUS and TTP
por: Kelen, Kata, et al.
Publicado: (2023)

Genetics and complement in atypical HUS
por: Kavanagh, David, et al.
Publicado: (2010)

Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies
por: Trojnar, Eszter, et al.
Publicado: (2019)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Case Report: Neonatal Unexplained HUS Treated With Complement Inhibitor Eculizumab
por: Kelen, Dorottya, et al.
Publicado: (2021)

COVID-19 as a potential trigger of complement-mediated atypical HUS
por: El Sissy, Carine, et al.
Publicado: (2021)

Non-lupus full-house nephropathy—immune dysregulation as a rare cause of pediatric nephrotic syndrome: Questions
por: Horváth, Orsolya, et al.
Publicado: (2021)

Non-lupus full-house nephropathy—immune dysregulation as a rare cause of pediatric nephrotic syndrome: Answers
por: Horváth, Orsolya, et al.
Publicado: (2021)

Follow-Up of Blood Pressure, Arterial Stiffness, and GFR in Pediatric Kidney Transplant Recipients
por: Végh, Anna, et al.
Publicado: (2021)

Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
por: Trojnár, Eszter, et al.
Publicado: (2017)

Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective
por: Kumar, Meet, et al.
Publicado: (2015)

How to define and assess the clinically significant causes of hematuria in childhood
por: Horváth, Orsolya, et al.
Publicado: (2022)

Publisher Correction: How to define and assess the clinically significant causes of hematuria in childhood
por: Horváth, Orsolya, et al.
Publicado: (2023)

Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality
por: Ardissino, Gianluigi, et al.
Publicado: (2021)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Editorial: Complement and COVID-19 Disease
por: Prohászka, Zoltán, et al.
Publicado: (2022)

Atypical HUS relapse triggered by COVID-19
por: Ville, Simon, et al.
Publicado: (2021)

First-line therapy in atypical hemolytic uremic syndrome: consideration on infants with a poor prognosis
por: Szarvas, Nóra, et al.
Publicado: (2014)

Atypical HUS with multiple complement system mutations triggered by synthetic psychoactive drug abuse: a case report
por: Jelicic, Ivo, et al.
Publicado: (2023)

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2010)

Validation of Early Increase in Complement Activation Marker sC5b-9 as a Predictive Biomarker for the Development of Thrombotic Microangiopathy After Stem Cell Transplantation
por: Mezö, Blanka, et al.
Publicado: (2020)

Atypical HUS Associated with CFH/CFHR-1 Hybrid Gene
por: Negi, Sharon, et al.
Publicado: (2020)

Atypical HUS Triggered by COVID-19: A Case Report
por: Tiwari, Vaibhav, et al.
Publicado: (2022)

Erratum to: aHUS caused by complement dysregulation: new therapies on the horizon
por: Waters, Aoife M., et al.
Publicado: (2012)

Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019)

Pulmonary Renal Syndrome due to Atypical HUS in a Young Gentleman
por: Rajarajan, Arun P., et al.
Publicado: (2023)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
por: Teoh, Chia Wei, et al.
Publicado: (2018)

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS
por: Valoti, Elisabetta, et al.
Publicado: (2019)

Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak
por: Brady, Tammy M, et al.
Publicado: (2016)

The Rationale of Complement Blockade of the MCP(ggaac) Haplotype following Atypical Hemolytic Uremic Syndrome of Three Southeastern European Countries with a Literature Review
por: Turudic, Daniel, et al.
Publicado: (2023)

Expanding Horizons in Complement Analysis and Quality Control
por: Frazer-Abel, Ashley, et al.
Publicado: (2021)

Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
por: Benoit, Stefanie W., et al.
Publicado: (2022)

Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J., et al.
Publicado: (2022)

Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS
por: Ermini, Luca, et al.
Publicado: (2012)

Correction to: Exploratory Prognostic Biomarkers of Complement-Mediated Thrombotic Microangiopathy (CM-TMA) in Adults with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of a Phase III Study of Ravulizumab
por: Cammett, Tobin J, et al.
Publicado: (2023)

Primary Sclerosing Cholangitis in Crohn’s Disease: An Atypical Complication
por: Ward, Mindy C, et al.
Publicado: (2021)

An Atypical Presentation of Crohn's Disease: A Case Report
por: Cheema, Asfand Yar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mv4fvd5u195nb9jv2gmni0r8d2